Teva Pharma (TEVA) Tops Q3 EPS by 9c

Teva Pharma (NYSE: TEVA) reported Q3 EPS of $1.32, $0.09 better than the analyst estimate of $1.23. Revenue for the quarter came in at $5.06 billion versus the consensus estimate of $5.09 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Medtronic completes $550 million Scientia Vascular acquisition
• MIND Technology (MIND) Misses Q1 EPS by 5c